Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adults and children over 6 months old and bodyweight \> 5 kg~* Able to be treated by oral route~* Axillary temperature ≥ 37,5 C or history of fever during the previous 2 days~* Symptomatic biologically confirmed Plasmodium vivax mono-infection, with parasitemia from 250 to 100000 parasites /µl of blood~* Written informed consent of the patients and for children written informed consent of the parents/legal representative for children. Children able to understand the objectives and the risks of the study will sign an assent form.~Exclusion criteria:~* Known project of leaving the investigator site area during the follow-up period (42 days)~* Hypersensitivity to one of the investigational medicinal products or to any of the excipients~* Intake of an antimalarial treatment in the previous 30 days~* History of hepatic and (or) haematological impairment during treatment with amodiaquine~* Blurred vision suggesting a retinopathy~* Presence of at least one danger sign of malaria~* Pregnant or breast-feeding women~* Women with childbearing potential not willing to use an effective contraceptive method(s) for the duration of the study~* Known severe concomitant or underlying disease~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- artesunate/amodiaquine (Type: EXPERIMENTAL): artesunate (AS) / amodiaquine (AQ) as fixed dose combination~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment
- chloroquine (Type: ACTIVE_COMPARATOR): 150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).